News

German pharma firm signs deal worth up to $1bn with QUB spin out
Re-Vana Therapeutics develops products to improve the delivery of drugs for chronic eye diseases, increasing the quality of ...
15 regions chosen for groundbreaking effort to reduce cardiovascular disease
July 28, 2025 - DALLAS People in 15 regions across the U.S. will soon benefit from the American Heart Association's ...
Veeva OpenData and Veeva Network Enable Coordinated Customer Engagement for Boehringer Ingelheim
Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...
Fierce Biotech3h
Boehringer eyes $1B deal to use Re-Vana’s drug delivery tech on ophthalmic pipeline
Boehringer Ingelheim is continuing to explore its newfound enthusiasm for eye health, penning a $1 billion biobucks pact with ...
BioSpace1h
Boehringer Links with Irish Drug Delivery Start-Up Re-Vana in $1B+ Eye Deal
The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable ...
The Pharma Letter4h
Boehringer inks ophthalmic deal with Re-Vana
Boehringer Ingelheim and Re-Vana Therapeutics, a USA and UK based developer of ocular therapeutics and ocular drug delivery ...
pharmaphorum2h
Bayer files HER2+ lung cancer drug in China
Bayer's rivalry with Boehringer Ingelheim in the development of medicines for HER2-mutated non-small cell lung cancer (NSCLC) ...
Queen’s University spin-out in landmark $1bn German pharma deal
Queen’s University Belfast spin-out company Re-Vana Therapeutics has signed a landmark collaboration deal with German ...
Belfast News Letter on MSN4h
Queen’s spin-out signs over $1 billion collaboration deal with pharma giant to revolutionise eye disease treatment from Belfast to the world
Re-Vana Therapeutics partners Boehringer Ingelheim to develop long-acting eye treatments positioning Northern Ireland as a ...
Boehringer Ingelheim Limited: Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast ...
Queen’s University spin-out company secures $1bn ‘eye deal’ partnership
A Belfast company Re-Vana Therapeutics – a spin-out from Queen’s University – has signed a major collaboration deal that could be worth more than $1bn.
Fierce Biotech4d
'Crossing fingers': Boehringer awaits key FDA decisions to spearhead 'maturing' pipeline
It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...